Pure Global AI
NCT06349967Not yet recruiting

Nab-paclitaxel Combined With Cadonilimab (AK104) for the Second-line Treatment of Advanced Gastric Cancer

Nab-paclitaxel Combined With Cadonilimab (AK104) for the Second-line Treatment of Advanced Gastric Cancer: A Prospective, Multicenter, Single-arm, Phase II Study
West China HospitalPhase 2ClinicalTrials.govdrug
Verified
Study focus
Disease/Condition
Gastric Cancer
Drug/Device/Intervention
Nab-paclitaxel Combined With Cadonilimab (AK104)
Study type
Interventional
Intervention type
drug
Sponsor & location
Primary sponsor
West China Hospital
Timeline & enrollment
Phase
Phase 2
Start date
Apr 30, 2024
End date
May 30, 2027
Enrollment
59 participants
Primary outcome

overall response rate (ORR)

Summary

Currently, standard treatment options for gastric cancer failed to first-line treatment
 include monotherapy with paclitaxel/irinotecan/docetaxel/albumin paclitaxel, or paclitaxel
 combined with ramucirumab. However, the efficacy of these regimens is still far from
 satisfactory. The aim of the study is to evaluate the efficacy and safety of nab-paclitaxel
 combined with cadonilimab for the second-line treatment of advanced gastric cancer.

ICD-10 classifications
Gastric ulcerMalignant neoplasm of stomachMalignant neoplasm: Body of stomachCarcinoma in situ: StomachMalignant neoplasm: Stomach, unspecified
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06349967
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06349967 through Pure Global AI's free database. This Phase 2 trial is sponsored by West China Hospital and is currently Not yet recruiting. The study focuses on Gastric Cancer. Target enrollment is 59 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.